Clinical Trial

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-03-22; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2023-05-05
Trial Details
NCT Number NCT05782270
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Anticoagulation, Coronary Endarterectomy
Enrollment 202 participants
Start Date 2023-04-11
Primary Completion 2025-09-25 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-18